Gene silencing and haploinsufficiency of Csk increase blood pressure by 이영호
RESEARCH ARTICLE
Gene Silencing and Haploinsufficiency of Csk
Increase Blood Pressure
Hyeon-Ju Lee1☯, Ji-One Kang1☯, Sung-Moon Kim1, Su-Min Ji1, So-Yon Park1, Marina
E. Kim1, Baigalmaa Jigden1, Ji Eun Lim1, Sue-Yun Hwang3, Young-Ho Lee2,
Bermseok Oh1*
1 Department of Biochemistry and Molecular Biology, School of Medicine, Kyung Hee University, Seoul,
Korea, 2 Department of Physiology, College of Medicine, Yonsei University, Seoul, Korea, 3 Department of
Chemical Engineering, College of Engineering, HanKyong National University, Ansung-Si, Gyeonggi-Do,
Korea




Recent genome-wide association studies have identified 33 human genetic loci that influ-
ence blood pressure. The 15q24 locus is one such locus that has been confirmed in Asians
and Europeans. There are 21 genes in the locus within a 1-Mb boundary, but a functional
link of these genes to blood pressure has not been reported. We aimed to identify a causa-
tive gene for blood pressure change in the 15q24 locus.
Methods and Results
CSK and ULK3 were selected as candidate genes based on eQTL analysis studies that
showed the association between gene transcript levels and the lead SNP (rs1378942).
Injection of siRNAs for mouse homologs Csk, Ulk3, and Cyp1a2 (negative control) showed
reduced target gene mRNA levels in vivo. However, Csk siRNA only increased blood pres-
sure while Ulk3 and Cyp1a2 siRNA did not change it. Further, blood pressure in Csk+/- het-
erozygotes was higher than in wild-type, consistent with what we observed in Csk siRNA-
injected mice. We confirmed that haploinsufficiency of Csk increased the active form of Src
in Csk+/- mice aorta. We also showed that inhibition of Src by PP2, a Src inhibitor decreased
high blood pressure in Csk+/- mice and the active Src in Csk+/- mice aorta and in Csk knock-
down vascular smooth muscle cells, suggesting blood pressure regulation by Csk through
Src.
Conclusions
Our study demonstrates that Csk is a causative gene in the 15q24 locus and regulates
blood pressure through Src, and these findings provide a novel therapeutic target for the
treatment of hypertension.
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Introduction
Blood pressure is influenced by a variety of mechanisms that involve many genetic factors. To
detect genetic markers for blood pressure, genome-wide association studies (GWASs) have
been performed using large human samples from various ethnic groups and have identified
many genetic loci that are associated with blood pressure and hypertension. The Korean Asso-
ciation REsource (KARE) [1], the Global Blood Pressure Genetics (GlobalBPgen) [2], Cohorts
for Heart and Aging Research in Genome Epidemiology (CHARGE) [3], the Asian Genetics
Epidemiology Network Blood Pressure (AGEN-BP) [4], and International Consortium for
Blood Pressure (ICBP) [5] have conducted GWASs on blood pressure and hypertension, iden-
tifying 33 independent loci that have reached a genome-wide significance level.
The 15q24 locus is significantly associated with blood pressure in Asians and Europeans, as
reported by Global BPgen [2] (rs1378942, P = 2×10−6 with systolic blood pressure (SBP),
P = 6×10−8 with diastolic blood pressure (DBP), N = 34,433 Europeans), the CHARGE consor-
tium [3] (rs6495122, P = 2.7×10−5 with SBP, P = 1.8×10−7 with DBP, N = 29,136 Europeans),
AGEN [4] (rs1378942, P = 6.5×10−6 with SBP, P = 1.0×10−5 with DBP, N = 41,447 Asians),
and ICBP [5] (rs1378942, P = 5.7×10−23 with SBP, P = 2.7×10−26 with DBP, N = 69,395 Euro-
peans). This link has also been confirmed by Takeuchi et al. [6] (rs1378942, P = 0.05 with SBP,
P = 0.009 with DBP, N24,300 Japanese), Tabara et al. [7] (rs1378942, P = 0.007 with SBP,
P = 0.015 with DBP, N = 13,920 Japanese), Hong et al. [8] (rs1378942, P = 2.48×10−5 with SBP,
P = 4.58×10−5 with DBP, N = 8,842 Koreans), and Ganesh et al. [9] (rs7085, P = 6.68×10−11
with SBP, P = 7.936×10−11 with DBP, N = 61,619 Europeans).
In the 15q24 locus, there are at least 21 genes near the lead SNP (rs1378942) within a 1-Mb
boundary. Among these genes, several Expression Quantitative Trait Loci (eQTL) analysis
studies have shown that the expression levels of CSK (c-src tyrosine kinase) and ULK3 (unc-
51-like kinase3) are significantly associated with polymorphism of rs1378942 in blood, lym-
phoblastoid cell lines (LCLs), and monocytes (CSK, P = 1.97×10−45, P = 1.27×10−129 in blood,
P = 2.386×10−13 in LCLs; ULK3, P = 3.17×10−17 in blood, P = 1.043×10−20 in LCLs,
P = 3.21×10−35 in monocytes) (S1 Table) [10–13]. These eQTL associations suggest CSK and
ULK3 as strong candidates for a causative gene of the 15q24 locus. CSK, C-terminal Src kinase,
down regulates the tyrosine kinase activity of Src, a proto-oncogene [14] and Csk is involved in
vascular development since the Csk knockout mouse embryo fails to form normal sprouting
and to remodel the vascular network [15]. Activation of Csk by angiotensin II (Ang II; a vaso-
constrictor) is reduced in vascular smooth muscle cells (VSMCs) from Spontaneously Hyper-
tensive Rats (SHR), leading to activation of Src, a target of Csk [16].
ULK3, serine/threonine kinase, mediates Hedgehog signaling during embryonic develop-
ment and has been implicated in the maintenance of tissue homeostasis and neurogenesis in
adults [17]. During the cell cycle, phosphorylation of Ulk3 is important in the G2/M phase,
suggesting a role in cell cycle progression [18].
There has been no functional study to support the link of these genes to blood pressure.
Based on eQTL analysis studies, mouse homologs Csk, Ulk3, and Cyp1a2 (negative control)
were examined for blood pressure change in siRNA-injected mice after testing for in vivo
silencing by siRNAs injection. We showed that only Csk siRNA injection increased blood pres-
sure while Ulk3 and Cyp1a2 siRNA injections did not change it. Our results along with the
eQTL analysis indicate that CSK is a causative gene in the 15q24 locus. We also confirmed that
haploinsufficiency of Csk increased blood pressure in Csk+/- heterozygote mice compared to
the wild-type. Further, inhibition of Src, a Csk target ameliorated hypertension in Csk+/- het-
erozygote mice, suggesting that Csk regulates blood pressure through Src.
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Materials and Methods
Animal research and ethics statement
All mice were housed and handled in a pathogen-free facility of College of Pharmacy at Kyung
Hee University in compliance with the Guide for the Care and Use of Laboratory Animals,
fully accredited by the Association for Assessment and Accreditation of Laboratory Animal
Care. The mice were maintained on a 12-hour light/dark cycle at a constant temperature with
free access to food (LabDiet 5L79, St. Louis, MO, USA) and water. Every effort was made to
minimize the number of sacrificed animals and their suffering. Animals were anesthetized by
intraperitoneal (i.p.) injection of tribromoethanol (18 ml of the working solution per kg body
weight), of which the working solution was diluted 40-fold in 0.9% NaCl from the stock solu-
tion (10 g 2,2,2, tribromoethanol dissolved in 10 ml tertiary amyl alcohol) and euthanized by
removing the heart. The experiment was approved by the local committee for the Care and Use
of Laboratory Animals, College of Pharmacy Institutional Animal Care and Use Committee
(license number: KHP-2010-04-06).
Female BALB/c mice (Japan SLC, Inc., Shizuoka, Japan) were used at age 7–9 weeks for
experiment. Csk knockout heterozygote mice, B6.129S-Csktm1Sor/J, were purchased from The
Jackson Laboratory (Bar Harbor, ME). Heterozygote and wild-type homozygote pairs were
mated, and the progeny was genotyped by PCR with the primer set using the wild-type (5’-
CGCAGTCTACGAGGTGATGA-3’), the mutant (5’-CCTTCTATCGCCTTCTTGACG-3’)
and the common reverse primer (5’-GGGCTCAGTTCAAGTTCAGG-3’).
The in vivo delivery of siRNA
The selection and in vivo delivery of siRNA have been previously described [19–21]. In brief,
more than 3 siRNAs per gene (Csk, Ulk3, and Cyp1a2) were synthesized by Genolution (Seoul,
Korea), and only one of them was selected for in vivo injection. To determine their silencing
efficacy, 20 nM of the siRNAs was transfected into B16F10 cells and NIH3T3 cells using G-Fec-
tin (Genolution, Seoul, Korea) and Lipofectamine 2000 (Invitrogen, Carlsbad, CA) respectively
according to their manufacturer’s instructions. TRP53 siRNA was used as a positive control for
all in vitro transfection experiments. The target siRNAs and scrambled control siRNA
sequences are shown in S4 Table.
For the in vivo delivery into mice, polyethylenimine called as in vivo-jetPEI™ (Polyplus, 201-
10G, Illkirch-Graffenstaden, France) was used as the transfection reagent. According to the
manufacturer’s instruction, 50 μg of siRNA and 6.5 μl of in vivo-jetPEI (N/P charge ratio of 6)
were diluted with 50 μl of 10% glucose solution and 50 μl of sterile H2O. The solution was vor-
texed gently and left for 15 min at room temperature. The mixture was injected into the tail
veins of 7–9-week-old, female BALB/c mice, and 24 hours after the last injection, the treated
mice were used for experiments (i.e., blood pressure measurement, collection of tissues for
mRNA quantitation or for Western blotting analysis). The 1-, 2- or 3-time injection means
once per day for 1, 2, or 3 days.
Quantitative real-time PCR
Total RNA was extracted from the tissues of siRNA-injected mice 24 hours after the last injec-
tion using TRIzol (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized from 500 ng of
total RNA using the PrimeScript™ RT kit (TaKaRa, Shiga, Japan) according to the manufactur-
er’s protocol. Quantitative real-time PCR analysis was performed using SYBR Green I
(TaKaRa, Shiga, Japan) on the ABI Step One Real-Time PCR system (Applied Biosystems,
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Foster, CA) using the following program: 45 cycles at 95°C for 10 s, 60°C for 15 s, and 72°C for
20 s. The primer sequences are shown in S5 Table.
To present the data as the fold-change of relative expression of “case” (e.g. target siRNA-
treated, Csk+/-) over “control” (e.g. control siRNA-treated, Csk+/+), the 2-ΔΔCt method was used
as previously described [22]. First, the Gapdh Ct value was subtracted from each target gene Ct
value to obtain the delta Ct (ΔCt) value for normalization and the ΔCt of the “control” sample
was averaged. Second, the averaged ΔCt value of the “control” sample was subtracted from
each ΔCt value of the “case” sample to obtain the delta delta Ct (ΔΔCt = ΔCt case—ΔCt con-
trol). Third, the ΔΔCt values are converted to the linear form using the term 2-ΔΔCt. The Stan-
dard Error of the Mean (SEM) is calculated from the final 2-ΔΔCt values. Statistical significance
was calculated for differences between the 2-ΔCt values of the “control” and those of the “case”
samples.
Culture of VSMC
The T/G HA-VSMC (vascular smooth muscle cell) line (CRL-1999) was purchased from
ATCC (American Type Culture Collection, Virginia, USA). This line of VSMC is a normal
human cell line established from the normal aorta of an 11-month old child and one of the
best-characterized cellular models for the analysis of vascular smooth muscle cell biology. Cells
were cultured in F-12K Medium (ATCC, No. 30–2004) supplemented with 0.05 mg/ml ascor-
bic acid, 0.01 mg/ml bovine insulin, 0.01 mg/ml human transferrin, 10 ng/ml sodium selenite,
0.03 mg/ml Endothelial Cell Growth Supplement, 10 mMHEPES, 10 mM TES, and 10% fetal
bovine serum under a 5% CO2 in air-ventilated incubator. To knock-down Csk, VSMCs were
transiently transfected with control or Csk siRNA using Lipofectamine 2000 and treated for 24
hours with DMSO or PP2 after 24 hours transfection and then proteins were extracted for
Western blotting.
Western blotting
Total proteins were extracted from mouse tissues using PRO-PREP protein extraction solution
(Intron Biotechnology, Gyeonggi-Do, Korea) according to the manufacturer's instruction. Pro-
tein concentrations were measured by Bradford assay [23].
Total proteins (10 to 40 μg) were separated by 8–10% SDS-PAGE and transferred to a nitro-
cellulose membrane (Pall, Ann Arbor, MI, USA). The membrane was blocked in 5% skim milk
for 30 min at room temperature and subsequently incubated with an antibody overnight at
4°C; anti-Actin (sc-1616, goat polyclonal, 1:1000), and anti-Csk (sc-286, rabbit polyclonal,
1:1000) from Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-phospho-SrcY416 (#2101,
rabbit polyclonal, 1:1000), anti-phospho-SrcY527 (#2105, rabbit polyclonal, 1:1000), and anti-
Src (#2123, rabbit polyclonal, 1:2000) from Cell Signaling Technology (Danvers, MA, USA).
The blot was incubated with a horseradish peroxidase-conjugated secondary antibody (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA) for 1 hour at room temperature. Protein sig-
nals were detected using Luminol Reagent (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA) and exposed to x-ray films (Agfa-Health Care NV, Mortsel, Belgium).
Blood pressure measurement
The protocol for blood pressure measurement has been previously described [19–21]. In brief,
blood pressure was recorded intra-arterially with a computerized data acquisition system (AD
Instruments, Bella Vista, Australia). First, mice (7-9-week old, female, 20–25 g) were anesthe-
tized by intraperitoneal (i.p.) injection of tribromoethanol (18 ml of the working solution per
kg body weight), of which the working solution was diluted 40-fold in 0.9% NaCl from the
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stock solution (10 g 2,2,2, tribromoethanol dissolved in 10 ml tertiary amyl alcohol). The intra-
arterial catheter (a polyethylene tube; 0.2 mm I.D., 0.5 mm O.D.; Natsume, Tokyo, Japan) filled
with 0.9% NaCl containing 100U/ml heparin was connected to the system. Second, while on
anesthetics, a small incision was made to draw out the right carotid artery of the mouse. The
catheter was inserted into the right carotid artery through a small puncture and tightly ligated
with 4–0 silk suture thread around the artery. Third, blood pressure in the vessel was transmit-
ted along the catheter to the transducer’s diaphragm (MLT0699 Disposable BP Transducer,
AD Instruments, Bella Vista, Australia). The diaphragm signal was amplified through a bridge
amplifier and recorded on a Power Lab system (Lab Chart 7.2, AD Instruments, Bella Vista,
Australia).
Blood pressure was monitored for 2 hours after injection of the anesthetic and presented as
the average value at each minute between 40 and 80 min (a linear graph) and as the average
value during 40 minutes from 40 to 80 min (a bar graph) because blood pressure during the
presented period was considered enough stable as evidenced by multiple repeated experiments.
To test the effect of PP2 (Merck Millipore, 529573, Darmstadt, Germany) or PP3, a negative
control inhibitor (Merck Millipore, 529574, Darmstadt, Germany), blood pressure was mea-
sured in Csk+/- and Csk+/+ mice 24 hours after i.p. injection of PP2 or PP3 at doses of 2 or 10 μg
per kg body weight.
Statistical analysis
Statistical analysis was performed using SPSS (PASW Statistics 22.0), and all data between case
and control groups were analyzed by Mann-Whitney U-test since the U-test was in general
considered more powerful than the t-test [24]. All data were expressed as mean ± SEM.
P< 0.05 was considered statistically significant.  P<0.05,  P<0.01 versus respective
controls.
Results
Injection of Csk, Ulk3, and Cyp1a2 siRNA reduces their respective target
mRNA levels in mouse tissues
Fig 1A shows the locations of nearby genes including CYP1A2, CSK, and ULK3 on the human
15q24 locus with the comparable gene locations on mouse chromosome 9 in the opposite
direction. The lead SNP (rs1378942 designated as ) is located in the first intron of CSK. To test
the effect of candidate gene variation on blood pressure, we used silencing of candidate genes
by siRNA injection into mice in vivo. Both mouse homologs Csk and Ulk3 were selected as
comparably strong candidate genes among nearby genes on the 15q24 locus based on eQTL
analysis studies (S1 Table). Cyp1a2 was tested as a negative control because there has been
reported neither significant association with blood pressure in GWAS or significant link to the
lead SNP (rs1378942) in eQTL resources (S1 and S3 Tables). Regarding its functional role,
CYP1A2 is associated with habitual caffeine consumption, and mediates drug metabolism and
the synthesis of cholesterol, steroids, and lipids (S3 Table) [25, 26].
Three siRNAs per gene were synthesized and tested for their silencing efficacies in NIH3T3
and B16F10 cells, and the most effective siRNA was selected for in vivo injection (S4 Table).
The selected siRNAs caused Csk, Ulk3, and Cyp1a2 levels to decline by 40.1%, 74.5%, and
44.9% in cells, respectively. The siRNAs were mixed with polyethylenimine and injected into
mouse tail veins. Then, to estimate the systemic change by siRNA injection, we measured target
genes mRNA levels 24 hours later by quantitative real-time PCR, comparing them between
candidate gene siRNA- and control siRNA-injected mouse tissues.
CSK, a Causative Gene in Hypertension
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After 1-time injection, CskmRNA levels decreased significantly in heart by 37% (P = 0.038),
in kidney by 20% (P = 0.038), and in lung by 29% (P = 0.017), respectively, and Ulk3mRNA
levels fell in lung by 32% (P = 0.001) (Fig 1B and 1C). Cyp1a2mRNA levels fell in liver by 49%
(P = 0.036) and in kidney 21% (P = 0.032) (Fig 1D).
Csk siRNA injection increases blood pressure
To study the functional effect of siRNA injection, blood pressure was measured 24 hours after
the last injection of Csk, Ulk3, or Cyp1a2 (negative control) siRNAs.
After 2-time injection, blood pressure did not change in Cyp1a2 siRNA-injected group
(74.3 mmHg, N = 6) compared with control groups (75.2 mmHg, N = 6) (P = 1.000) (Fig 2G and
2H). However, Csk siRNA-injected mice (88.2 mmHg, N = 7) showed significantly increased
blood pressure compared with control groups (74.9 mmHg, N = 7) (P<0.001) (Fig 2A and 2B).
Interestingly Ulk3 siRNA-injected mice (74.3 mmHg, N = 7) did not show significant changes in
blood pressure versus control mice (73.9 mmHg, N = 8) (P = 1.000) (Fig 2D and 2E).
To confirm reduction of the target gene mRNA, Csk, Ulk3, and Cyp1a2mRNA levels were
measured in mice tissues after 2-time injection of each siRNA. CskmRNA levels decreased sig-
nificantly in heart by 31% (P = 0.001) and in liver by 19% (P = 0.01), respectively, and Ulk3
mRNA levels also decreased in liver by 34% (P = 0.001), in spleen by 37% (P = 0.001), and in
lung by 44% (P = 0.003), respectively (Fig 2C and 2F). Cyp1a2 transcripts also fell in liver by
32% (P = 0.045) after 2-time injection (Fig 2I). The results showed that only Csk gene knock-
Fig 1. Location of candidate genes in the 15q24 GWAS locus and reduction of target gene mRNAs in siRNA-injected mice. (A) Positions of candidate
genes are comparably shown on the human 15q24 locus and on the homologous mouse chromosome 9, 31.18 cM in the opposite direction; * indicates
position of rs1378942, the lead SNP for blood pressure GWASs in the 15q24 locus. (B) The relative expression of candidate gene mRNAs in each tissue is
presented as the fold change of relative mRNA levels in candidate gene versus control siRNA-injected mice after 1-time siRNA injection. Error bars show the
mean ± SEM. Number in parentheses indicates the pair number of mice used for real-time PCR analysis. P values were calculated by Mann-Whitney U-test.
* P<0.05 versus respective controls.
doi:10.1371/journal.pone.0146841.g001
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down induced a significant change in blood pressure although all three genes (Csk, Ulk3, and
Cyp1a2) were knock-downed by siRNA injections in various tissues.
Csk protein levels stay decreased in mouse tissues after siRNA injection
To test the lasting effect of siRNA silencing, Csk siRNAs were injected into mice once per day
for 3 days (3-time injection). Blood pressure significantly differed between Csk siRNA-treated
Fig 2. Increase in blood pressure inCsk siRNA-injected mice. (A, D, and G) The line graph shows blood pressure as the average value at each minute
from 40 min to 80 min after anesthesia in (A) 2- timeCsk siRNA-, (D) 2-timeUlk3 siRNA-, and (G) 2-timeCyp1a2 siRNA-injected mice. (B, E, and H) The bar
graph shows the mean blood pressure for each group from 40 min to 80 min. (C, F, and I) Graphs show the relative expression of candidate gene mRNA in
each tissue after 2-time siRNA injection. * P<0.05, ** P<0.01 versus respective controls.
doi:10.1371/journal.pone.0146841.g002
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PLOS ONE | DOI:10.1371/journal.pone.0146841 January 11, 2016 7 / 15
mice (87.4 mmHg, N = 7) and control mice (80.6 mmHg, N = 7) (P = 0.017) even after 3-time
injection (Fig 3A and 3B).
To study Csk protein levels in Csk siRNA-injected mice, Western blotting for Csk was per-
formed using mouse lung tissues. Csk protein levels declined after all 1-, 2- and 3-time injec-
tions in lung tissues (Fig 3C). After 2-time injection of Csk siRNA, Csk protein levels fell in
lung by 53% (P = 0.016) (Fig 3C and 3D). These data imply that Csk protein levels may stay
decreased systematically after repeated injections of siRNAs despite of rebounding mRNA
levels.
Blood pressure increases in Csk heterozygote mice
To confirm the blood pressure change in Csk siRNA-injected mice, we examined Csk knockout
mice. Because the Csk knockout homozygote (Csk-/-) was embryonic-lethal, the Csk heterozy-
gote (Csk+/-) mice were compared with the wild-type (Csk+/+) mice. The CskmRNA level in
Csk heterozygotes decreased in most tissues by half (Fig 4C). Consistent with the results in Csk
siRNA-injected mice, blood pressure in Csk+/- mice was significantly higher than in the wild-
type (Csk+/-, 86 mmHg, N = 12; Csk+/+, 80 mmHg, N = 15; P = 0.021) (Fig 4A and 4B).
Since Csk is a negative regulator of Src protein [14] and Src plays a role in contraction of
vascular smooth muscle cells [27], Western blotting analysis was performed for Csk and phos-
phorylated Src proteins in the aorta of Csk+/- and Csk+/+ mice. Csk protein levels were reduced
by 52% (P = 0.002) in the Csk+/- aorta (Fig 4D and 4E). While the total Src protein was not
changed in Csk+/- aorta, phosphorylation of SrcY416 (active) significantly increased by 38%
(P = 0.046) and that of SrcY527 (inactive) decreased by 25% (P = 0.01), suggesting Src as a target
of Csk in the aorta (Fig 4D and 4E).
Inhibition of Src decreases high blood pressure in Csk heterozygote
mice
To study whether Csk involves Src in modulating blood pressure, we examined the effect of
PP2, a Src inhibitor in Csk+/- mice. High blood pressure in Csk+/- mice (93.9 mmHg, N = 8)
was significantly reduced 24 hours after i.p. injection of 10 μg PP2 per kg body weight
(83.5 mmHg, N = 8; P = 0.038) (5A and 5B). Lesser dose of PP2 seemed to decrease blood pres-
sure without significance in Csk+/- mice (2 μg/kg PP2, 87.2 mmHg, N = 5, P = 0.284) while PP2
did not affect the basal blood pressure in the wild-type (0μg/kg, 80.2 mmHg, N = 8; 2 μg/kg,
Fig 3. Increase in blood pressure in 3-timeCsk siRNA-injected mice and change in protein levels inCsk siRNA-injected mice. (A) The line graph and
(B) the bar graph show blood pressure from 40 min to 80 min after anesthesia in 3-time Csk siRNA-injected mice. (C) Csk protein levels in lung are shown for
1-, 2-, and 3-time siRNA injected mice followingWestern blotting. (D) Csk protein levels in lung are presented as the ratio of 5 independent protein band
densities for 2-time siRNA injected mice.
doi:10.1371/journal.pone.0146841.g003
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82.1 mmHg, N = 8; 10 μg/kg, 80.2 mmHg, N = 10) (Fig 5B). We studied the effect of PP3, a
negative control inhibitor of PP2 and did not see any significant change of blood pressure by
its treatment (Csk+/+, 80 mmHg, N = 18; Csk+/-, 89 mmHg, N = 8; Csk+/- + 10 μg/kg PP3,
89 mmHg, N = 5), indicating that PP2 was specific in its effect on blood pressure (S1 Fig).
To confirm inhibition of Src by PP2, we performed Western blotting analysis for phosphor-
ylated Src proteins in the aorta of Csk+/- and Csk+/+ mice treated with 10 μg/kg PP2. As shown
in Fig 5C and 5D, phosphorylated SrcY416 (active) was significantly reduced in the PP2-treated
Csk+/- aorta compared to vehicle-treated aorta and phosphorylated SrcY527 (inactive) was also
slightly decreased.
Further to study regulation of Src by Csk in functionally relevant cell types, we cultured
human vascular smooth muscle cells (T/G HA-VSMC, ATCC), transfected cells with Csk
siRNA, and then treated with 10, 25, 50 μM PP2 for 24 hours. The Western blotting analysis
showed that phosphorylation of SrcY416 was conspicuously increased by Csk siRNAs transfec-
tion in VSMCs consistent with the result from the Csk+/- mice aorta (Fig 5E). Moreover, PP2
treatment dose-dependently decreased phosphorylation of SrcY416 in Csk siRNA-transfected
cells (Fig 5E). Phosphorylation of SrcY527 did not significantly change by Csk siRNAs transfec-
tion, but seemed to decrease by PP2 treatment in VSMCs (Fig 5E).
These results suggest that Src is specifically involved in blood pressure regulation by Csk.
Fig 4. Increase in blood pressure inCsk+/- mice. (A, and B) Blood pressure is expressed as (A) the average value at each minute and (B) the mean blood
pressure for each group from 40 min to 80 min after anesthesia in Csk+/- and the wild-type. (C) The relative expression ofCskmRNA in each tissue is
expressed as the fold change of relative levels inCsk+/- (N = 7) versus Csk+/+ (N = 5), normalized byGapdh. (D) The representative blots of Csk and
phosphorylated Src protein levels are shown followingWestern blotting in aorta ofCsk+/- andCsk+/+ mice. (E) Protein levels in aorta are presented as the
ratio of band densities for Csk+/- mice to those for Csk+/-. Number in parentheses indicates the number of mice used for the Western blotting.
doi:10.1371/journal.pone.0146841.g004
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Discussion
It has been a challenging task to identify a causative gene in a locus that is associated with
blood pressure. Therefore, there are very few genes identified as causative so far despite of mul-
tiple candidates associated with blood pressure GWASs. For that reason, we utilized two-step
approaches. First, we selected the most relevant candidate genes in a locus by using the eQTL
analysis studies. Then, we tested the effect of gene knock-down on blood pressure after the in
vivo delivery of candidate gene siRNA into mice.
We previously reported ATP2B1 in the 12q21 locus [20] as a causative gene by testing the
effect of target gene siRNA silencing on blood pressure. The recent eQTL study showed that
the expression of ATP2B1 transcripts was associated with rs1401982 and rs17249754
(rs1401982, P = 1.4×10−24 for all common SNPs; rs17249754, P = 5.5×10−4 for 1,167 trait-asso-
ciated SNPs in blood) [11], supporting our previous study using in vivo siRNA silencing. The
SORT1 gene is another good example that a specific gene is identified as associated with a vari-
ant (rs599839) in the 1p13 locus by an eQTL study (P = 6.11×10−55 in liver) and that rs629301
in LD with rs599839 is associated with plasma low-density lipoprotein cholesterol (LDL-C)
in GWAS (P = 1×10−170) [28, 29]. Musunuru et al. (2010) has clearly demonstrated that
rs12740374 in LD with rs599839 and rs629301 is a causative variant because its polymorphism
alters hepatic expression of the SORT1 gene and knockdown by Sort1 siRNA in mouse liver
changes plasma LDL-C levels [30].
Fig 5. Decrease in blood pressure by PP2, a Src inhibitor inCsk+/- mice. (A) Csk+/- andCsk+/+ mice were i.p. injected with DMSO as control (CON) or
PP2 (10 μg per kg body weight), a Src inhibitor, and blood pressure was measured 24 hours after injections. Blood pressure is expressed as the average
value at each minute from 40 min to 80 min after anesthesia. (B) Blood pressure was measured inCsk+/- andCsk+/+ mice treated with DMSO or PP2 (2, and
10 μg per kg body weight) and the data is shown as the mean blood pressure for each group from 40 min to 80 min. (C) The representative blots of Csk and
Src protein are shown followingWestern blotting in aorta of Csk+/- andCsk+/+ mice treated with DMSO or PP2 (10 μg per kg body weight). (D) Protein levels
are presented as the ratio of protein band densities in Csk+/- aorta to the wild-type. (E) Human VSMC cells were transfected by Csk siRNA and then treated
with DMSO or PP2 (10, 25, and 50 μM). Phosphorylated Src and Csk protein levels are shown followingWestern blotting.
doi:10.1371/journal.pone.0146841.g005
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In the present study we used the eQTL resources more aggressively to sort out prominent can-
didates. Through mining the eQTL resources, CSK andULK3were selected in the 15q24 locus
for further study. Target gene silencing was successfully tested in vivo according to the protocol
we have previously established. As a result, Csk in the 15q24 locus was identified as a causative
gene for the blood pressure change and furthermore confirmed in a knockout mouse model.
Therefore, the present study and previous ones support that in vivo siRNA silencing combined
with the eQTL analysis is a very useful tool to identify a causative gene among candidate genes.
However, we observed a difference in the directionality of the effect of suppression of Csk in
mice from the results obtained in human GWAS and eQTL studies that the ‘C’ allele of the lead
SNP (rs1378942) is associated with higher blood pressure and higher CSK transcripts [2, 5–7,
11, 12]. We considered three possible reasons for the conflicting results. One possibility is a
molecular and functional difference between the human CSK and mouse Csk gene. But it is
very unlikely since the human CSK and mouse Csk proteins are identical except one residue at
123 within SH2 domain, not within a functional domain such as the kinase domain. The other
one is a recording error for SNP alleles in eQTL databases. We personally corresponded with
authors of Fehrmann et al. (2011) and Grundberg et al. (2012) papers but were provided with a
solid confirmation for their databases. The third reason might be the lack of the functional tis-
sue in eQTL resources. We speculate that the correct eQTL data may be unavailable until the
functional tissue of CSK for blood pressure regulation is revealed. Despite of still unsolved con-
flicts, we believe that our results provide an important clue for how the decreased Csk gene
activity is associated with hypertension in Spontaneously Hypertensive Rats (SHR) [16], as
explained in the following section.
Csk regulates blood pressure through Src
Csk was identified as a tyrosine kinase of Src, a non-receptor tyrosine kinase [14]. Csk inactivates
Src by increasing phosphorylation of SrcY527, acting as a negative regulator of Src (Fig 6) [31].
Phosphorylation of SrcY416 is increased in the Csk+/- mouse aorta and in Csk knock-down cells
than in the wild-type (Fig 5C, 5D and 5E). Furthermore, inhibition of Src decreases high blood
pressure in Csk+/- mice (Fig 5A and 5B), strongly suggesting that hypertension occurs through Src.
Src is one member of eight Src family tyrosine kinases (c-Src, c-Yes, Fyn, c-Fgr, Lyn, Hck,
Lck, and Blk) [31]. Among them, the activity of Src is important in Ang II-induced vasocon-
striction of vascular smooth muscle cells (VSMCs). Ang II induces phosphorylation of SrcY416
via angiotensin type 1 receptor (AT1R) in rat VSMCs [32]. Ang II-induced intracellular Ca2+
mobilization is blunted in Src-/- VSMC and vascular contraction is inhibited by PP2, a Src
inhibitor [27]. Interestingly low activation of Csk is associated with increased Ang II-mediated
Src signaling in VSMCs of Spontaneously Hypertensive Rats (SHR) [16]. These reports and
our findings suggest that the Csk-Src signal may be a key regulatory point in Ang II-mediated
vasoconstriction and blood pressure regulation (Fig 6).
Downstream of the Csk-Src signal, extracellular signal-regulated kinases (ERK1/2) may play
an important role in vasoconstriction. In SHRs, inhibition of ERK signaling by U0126 reduces
hypertension, vascular thickening, and smooth muscle myosin light chain kinase expression
[33]. Moreover, Ang II-mediated ERK1/2 activation requires Src in rat VSMCs [16, 34]. There-
fore, we speculate that Csk negatively modulates Ang II-mediated Src/ERK signaling in vaso-
constriction of VSMCs.
Src plays important roles in Ang II-mediated signaling in multiple tissues
Ang II is a major effector hormone of the renin-angiotensin system and has various effects that
are mediated by AT1R to raise blood pressure, including direct vasoconstriction in the vascular
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smooth muscle, indirect vasoconstriction by noradrenaline release from the sympathetic nerve
system, sodium reabsorption in the kidney, sodium and fluid retention by aldosterone secre-
tion from the adrenal gland, and vascular growth stimulation [35].
In addition to already mentioned role of Src in VSMCs, Src activation is required for Ang II-
mediated functions in the kidney and in the brain. In the renal proximal tubule-like cells, PP2
and Src siRNA inhibits Ang II-induced epithelial-to-mesenchymal transition (EMT) associated
with progressive kidney damage [36]. Also Src is activated in Ang II-induced fluid reabsorption
via apical Na+/H+ exchanger (NHE) and basolateral Na+-HCO3
- cotransporter (NBC) and Csk
overexpression inhibits activation of both NHE and NBC [37, 38]. In the distal tubule of kidney,
Src is required for inhibition of the renal outer medullary potassium (ROMK) channel during
hypovolemia (low blood volume) by low potassium diet [39–42]. Therefore, hypertension by low
potassium diet may be associated with the inhibitory effect of Src on the ROMK channel.
In the hypothalamus of hypertensive rats induced by two-kidney one-clip (2K1C), Src acti-
vation is higher than sham-operated rats and is more increased by Ang II [43]. Two specific
Src inhibitors (PP2, SU6656) abolish increase in sympathetic nerve activity and blood pressure
of 2K1C rats, suggesting that Src in the brain mediates sympathetic activation by renovascular
hypertension.
Considering that Src plays regulatory roles in diverse tissues, hypertension in Csk+/- mice
may rather be the combined result of differential effects by chronic Src activation in multiple
tissues (e.g., vasculature, kidney, or/and brain) than the result of a defect in one particular tis-
sue. Therefore, to fully understand the mechanism of hypertension in Csk+/- mice, changes in
Src-associated signaling need to be further studied in each tissue.
In summary, we have identified CSK a causative gene in the blood pressure GWAS locus
15q24 by selecting candidate genes using the eQTL analysis studies, by verifying the functional
effect of genes using in vivo siRNA delivery in mice, and by confirming our findings in knock-
out heterozygote mice. Furthermore, we showed that Csk involves Src by negatively regulating
its activity to modulate blood pressure. Our result that Csk regulates blood pressure through
Src suggests a novel pathway for the development of hypertension and provides a therapeutic
target for the treatment of high blood pressure.
Fig 6. The workingmodel of blood pressure regulation by Csk and Angiotensin II through Src.
Angiotensin II (Ang II) increases blood pressure through angiotensin type 1 receptor (AT1R) dependent on
the Csk/Src signal. Csk, a negative regulator of Src increases phosphorylation of SrcY527 (inactive) and
decreases that of SrcY416 (active).
doi:10.1371/journal.pone.0146841.g006
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